Strategic focus Coave Therapeutics is a clinical stage biotech developing gene therapies for rare ocular and CNS diseases, with a proprietary ALIGATER platform (AAV-Ligand Conjugates) aimed at targeted delivery and enhanced transduction. This indicates potential sales opportunities with specialized contract research organizations, CROs, and ophthalmology/CNS-focused partners seeking advanced gene therapy capabilities.

Recent milestones Recent announcements include launch of OneAAV universal capsid and a CNS-targeted capsid program (coAAV-CSF-01), plus leadership in business development. These milestones signal near-term productization potential and collaboration readiness for partners seeking validated platform capabilities in gene delivery.

Financial momentum Secured €32 million (~$33 million) in Series A funding and current revenue in the low-to-mid single digits, indicating a growing company with capital to pursue partnerships, out-licensing opportunities, and collaborative development arrangements with pharma or biotech companies.

Strategic markets Focus areas include retinal vascular diseases (wet AMD, DME) and CNS targets, suggesting sales opportunities with ophthalmology device/biologic distributors, specialty ophthalmology clinics, academic centers, and CNS-focused research collaborations looking for cutting-edge gene therapy platforms.

Global footprint Presence in Paris and Cambridge (MA) with international leadership in business development positions Coave to engage cross-border collaborations, licensing deals, and multinational trials, expanding the potential pool of partners and customers for ALIGATER-based therapies.